Journal of Surgical Oncology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Oct. 29, 2024
ABSTRACT
The
global
incidence
of
hormone‐positive
breast
cancer
(HR+
BC)
in
young
women
is
rising,
though
the
underlying
reasons
remain
unclear.
HR+
disease
younger
appears
to
represent
a
distinct
clinical
entity
compared
that
older
women,
exhibiting
clinicopathological
characteristics,
outcomes
and
responses
treatment.
Despite
these
differences,
there
paucity
large‐volume
data
focusing
on
with
contemporary
literature.
Hormone
receptor
positive
associated
poorer
prognoses
women.
Additionally,
early
age
onset
presents
unique
challenges,
including
concerns
related
fertility,
toxic
effects
therapeutic
agents,
specific
surgical
considerations.
purpose
this
review
report
existing
literature
Gland Surgery,
Journal Year:
2024,
Volume and Issue:
13(6), P. 871 - 884
Published: June 1, 2024
Although
the
research
reports
on
locally
advanced
breast
cancer
(LABC)
are
increasing
year
by
year,
there
few
T1
LABC
axillary
lymph
node
metastasis
(ALNM).
By
establishing
a
prediction
model
for
ALNM,
this
study
provides
reference
value
probability
of
ALNM
related
patients,
which
helps
clinicians
to
develop
more
effective
and
individualized
treatment
plan
LABC.
Acta Obstetricia Et Gynecologica Scandinavica,
Journal Year:
2023,
Volume and Issue:
103(4), P. 775 - 778
Published: Nov. 20, 2023
Breast
cancer
is
the
most
common
malignancy
diagnosed
during
or
directly
after
pregnancy.
Differences
in
pathogenesis
and
prognosis
identify
two
distinct
patient
groups,
those
with
breast
pregnancy
postpartum
which,
for
reasons
not
completely
understood,
associated
worse
outcomes.
Compared
non-pregnant
patient,
several
limitations
terms
of
both
local
systemic
therapy
are
applied
to
limit
fetal
harm.
Treatment
nevertheless
delivered
curative
intent,
therefore
avoiding
harmful
delays
initiation,
unnecessary
de-escalation
chemotherapy
dose
modifications
strongly
recommended.
In
this
short
commentary,
we
briefly
review
current
evidence
treatment
guidelines
provide
recommendations
optimal
oncologic
management
pregnancy-related
cancer.
Journal of Surgical Oncology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Oct. 29, 2024
ABSTRACT
The
global
incidence
of
hormone‐positive
breast
cancer
(HR+
BC)
in
young
women
is
rising,
though
the
underlying
reasons
remain
unclear.
HR+
disease
younger
appears
to
represent
a
distinct
clinical
entity
compared
that
older
women,
exhibiting
clinicopathological
characteristics,
outcomes
and
responses
treatment.
Despite
these
differences,
there
paucity
large‐volume
data
focusing
on
with
contemporary
literature.
Hormone
receptor
positive
associated
poorer
prognoses
women.
Additionally,
early
age
onset
presents
unique
challenges,
including
concerns
related
fertility,
toxic
effects
therapeutic
agents,
specific
surgical
considerations.
purpose
this
review
report
existing
literature
